Triple-negative breast cancer
Conditions
Interventions
cyclophosphamide, epirubicin, capecitabine, docetaxel
Sponsors
Department of breast and endocrine surgery, Hyogo college of medicine
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. Histologically confirmed breast cancer aged between 20-70 years old female 2. Operable stage I-III (TNM) breast cancers 3. Estrogen receptor negative 4. Progesterone receptor negative 5. HER 2 negative: either 0, 1, 2 expression by IHC and FISH-negative 6. No prior treatment for breast cancer including chemotherapy, radiotherapy, endocrine therapy, immunotherapy 7. PS: 0-1 (ECOG) 8. Signed written informed consent
Exclusion criteria
Exclusion criteria: 1. Another cancer diagnosed within 5 years 2. Pregnant or nursing women 3. Male patients 4. With history of serious drug allergy 5. With interstitial pneumonitis or lung fibrosis 6. Infection or possible infection associated with clinical symptoms such as fever 7. With symptom of varicella 8. With uncontrollable pleural effusion, or pericardial effusion 9. With severe edema 10. With severe peripheral neuropathy 11. Usual treatment with steroid 12. With severe psychological complication 13. Bilateral breast cancer 14. Cases who physician judged improper to entry this trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pathological complete response | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical response, breast conserving rate, safety, DFS, OS | — |
Countries
Japan
Contacts
Public ContactYasuo Miyoshi
Hyogo college hospital Department of breast and endocrine surgery
Outcome results
None listed